Cognition Therapeutics, Inc.
CGTX
$1.20
$0.021.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 57.37% | 50.39% | 4.36% | 7.33% | 3.67% |
| Total Depreciation and Amortization | -14.08% | -12.86% | -8.96% | -22.41% | 7.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -25.28% | -41.74% | -45.86% | -57.10% | -50.14% |
| Change in Net Operating Assets | 51.62% | -161.51% | 352.35% | -519.88% | -173.97% |
| Cash from Operations | 59.00% | 17.52% | 6.24% | -36.35% | -53.63% |
| Capital Expenditure | -- | -- | -- | -- | 96.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 1,000.00% | -- | -- | -- | 96.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 62.05% | 77.84% | 33.70% | 33.71% | -8.94% |
| Issuance of Common Stock | -76.75% | -- | -37.09% | -88.11% | 392.93% |
| Repurchase of Common Stock | -- | 95.58% | 77.27% | 56.60% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -68.92% | -- | -- | -- | -- |
| Cash from Financing | -94.68% | 10,209.12% | 644.93% | -89.19% | 366.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -194.16% | 533.39% | 20.64% | -280.69% | 198.39% |